Table 1. Clinical and pathological features of patients with advanced gastric cancer (n = 50).
| Parameter | Value |
|---|---|
| Gender | |
| Male | 38 (76%) |
| Female | 12 (24%) |
| Age (years) | 60 (54, 66) |
| Pathologic type | |
| Well-differentiated | 4 (8%) |
| Moderately differentiated | 18(36%) |
| Poorly differentiated | 19 (38%) |
| Signet ring cell/mucinous | 9 (18%) |
| Tumour location | |
| Upper third | 9 (18%) |
| Middle third | 14 (28%) |
| Distal third | 27 (54%) |
| Surgery | |
| Total gastrectomy | 11 (22%) |
| Subtotal gastrectomy | 13 (26%) |
| Distal gastrectomy | 22 (44%) |
| Bypass | 4 (8%) |
| Tumour invasion deptha | |
| T2 | 9 (18%) |
| T3 | 21 (42%) |
| T4 | 16 (32%) |
| Unknown | 4 (8%) |
| Lymph node metastasisa | |
| N0 | 13 (26%) |
| N1 | 8 (16%) |
| N2 | 10 (20%) |
| N3 | 15 (30%) |
| Unknown | 4 (8%) |
| Distant metastasis | 6 (12%) |
| Peritoneal | 3 |
| Post-peritoneal lymph nodes | 2 |
| Organ | 1 |
| TNM stagea | |
| Stage IB | 6 (12%) |
| Stage II | 13 (26%) |
| Stage III | 25 (50%) |
| Stage IV | 6 (12%) |
| Surgical type | |
| R0 | 39 (78%) |
| Non-R0 | 11 (22%) |
| Tumour marker-positive | 20 (40%) |
aAccording to the 7th American Joint Committee on Cancer TNM classification.